The first study measured circulating galectin-1 in 989 individuals in Gothenburg, Sweden at the age of 40–65 years and investigated the association between serum galectin-1 and T2D independently of BMI, excluding individuals with a medical history of cancer or autoimmune diabetes. The gene discussed is LGALS1; the disease is cancer.